Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Qlaris Bio, Inc.

Qlaris Bio Announces Development of Fixed-Dose Combination Therapy with QLS‑111 and Latanoprost for the Treatment of Glaucoma
From Qlaris Bio, Inc.
Via Business Wire
Qlaris Bio Announces Positive Topline Data From Two Phase II Trials of QLS-111 in Patients With Primary Open Angle Glaucoma and Ocular Hypertension
From Qlaris Bio, Inc.
Via Business Wire
Qlaris Bio Completes $24 Million Series B Financing Round to Advance QLS‑111, a First-in-class IOP-lowering Drug Candidate for Glaucoma
From Qlaris Bio, Inc.
Via Business Wire
Qlaris Bio’s Novel IOP-Lowering Product, QLS‑111, is Dosed in Phase II Trials
From Qlaris Bio, Inc.
Via Business Wire
Qlaris Bio to Present at Glaucoma 360 New Horizons Forum
From Qlaris Bio, Inc.
Via Business Wire
Qlaris Bio Reports Phase 2 Clinical Trial Results Demonstrating Favorable Safety and Tolerability Profile and Positive Efficacy Signal for QLS-101
From Qlaris Bio, Inc.
Via Business Wire
Qlaris Bio Enrolls First Patient in Phase 1/2 Studies of QLS-101, an Investigational Therapy Designed to Lower Episcleral Venous Pressure (EVP) in Patients with Glaucoma
From Qlaris Bio, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.